Circassia Pharmaceuticals (LON:CIR) had its target price cut by equities research analysts at Peel Hunt from GBX 90 ($1.18) to GBX 70 ($0.91) in a report issued on Tuesday, Digital Look reports. The firm currently has a “buy” rating on the stock. Peel Hunt’s price target indicates a potential upside of 329.45% from the company’s previous close.

Separately, FinnCap assumed coverage on Circassia Pharmaceuticals in a research note on Thursday, September 26th. They set a “corporate” rating and a GBX 80 ($1.05) price target for the company. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Circassia Pharmaceuticals has an average rating of “Buy” and a consensus price target of GBX 79 ($1.03).

Shares of LON CIR opened at GBX 16.30 ($0.21) on Tuesday. The stock has a fifty day moving average price of GBX 17.31 and a two-hundred day moving average price of GBX 21.79. The company has a debt-to-equity ratio of 21.61, a quick ratio of 0.35 and a current ratio of 0.40. The firm has a market cap of $61.15 million and a P/E ratio of -0.48. Circassia Pharmaceuticals has a 1 year low of GBX 13.25 ($0.17) and a 1 year high of GBX 78.20 ($1.02).

In related news, insider Jonathan Emms acquired 300,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was bought at an average price of GBX 17 ($0.22) per share, for a total transaction of £51,000 ($66,640.53).

About Circassia Pharmaceuticals

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).

Featured Article: Dead Cat Bounce

Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with's FREE daily email newsletter.